Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial
Schmoll H, Mann J, Meinert F, Garlipp B, Borchert K, Vogel A, Goekkurt E, Kaiser U, Hoeffkes H, Rüssel J, Kanzler S, Edelmann T, Forstbauer H, Göhler T, Hannig C, Hildebrandt B, Roll C, Bokemeyer C, Steighardt J, Cygon F, Ibach S, Stein A, Tintelnot J
BRIT J CANCER. 2024;130(2):233-241.

A Multimodal Lifestyle Psychosocial Survivorship Program in Young Cancer Survivors: The CARE for CAYA Program-A Randomized Clinical Trial Embedded in a Longitudinal Cohort Study
von Grundherr J, Elmers S, Koch B, Hail L, Mann J, Escherich G, Bergelt C, Samland L, Jensen W, Vettorazzi E, Stark M, Valentini L, Baumann F, Singer S, Reer R, Beller R, Calaminus G, Faber J, Classen C, Gebauer J, Hilgendorf I, Koehler M, Puzik A, Salzmann N, Sander A, Schiffmann L, Sokalska-Duhme M, Schuster S, Kock-Schoppenhauer A, Bokemeyer C, Sinn M, Stein A, Dwinger S, Salchow J
JAMA NETW OPEN. 2024;7(3):e242375.

Effects of a structured counselling-based intervention to improve physical activity behaviour of adolescents and young adult cancer survivors - the randomized phase II Motivate AYA - MAYA trial
Salchow J, Koch B, Mann J, von Grundherr J, Elmers S, Dwinger S, Escherich G, Vettorazzi E, Reer R, Sinn M, Baumann F, Bokemeyer C, Stein A, Jensen W
CLIN REHABIL. 2021;35(8):1164-1174.

Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL
Nilsson S, Stein A, Rolfo C, Kranich A, Mann J, Papadimitriou K, Theile S, Amberg S, Bokemeyer C
CURR CANCER DRUG TAR. 2020;20(10):811-817.

Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors - presentation of the CARE for CAYA-Program study protocol and associated literature review
Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, Straub L, Vettorazzi E, Escherich G, Rutkowski S, Dwinger S, Bergelt C, Sokalska-Duhme M, Bielack S, Calaminus G, Baust K, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Gebauer J, Langer T, Metzler M, Schuster S, Niemeyer C, Puzik A, Reinhardt D, Dirksen U, Sander A, Köhler M, Habermann J, Bokemeyer C, Stein A
BMC CANCER. 2020;20(1):16.

Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes
Gottschalk M, Richter J, Ziegler C, Schiele M, Mann J, Geiger M, Schartner C, Homola G, Alpers G, Büchel C, Fehm L, Fydrich T, Gerlach A, Gloster A, Helbig-Lang S, Kalisch R, Kircher T, Lang T, Lonsdorf T, Pané-Farré C, Ströhle A, Weber H, Zwanzger P, Arolt V, Romanos M, Wittchen H, Hamm A, Pauli P, Reif A, Deckert J, Neufang S, Höfler M, Domschke K
TRANSL PSYCHIAT. 2019;9(1):75.

Impact of taste and smell training on taste disorders during chemotherapy – TASTE trial
von Grundherr J, Koch B, Grimm D, Salchow J, Valentini L, Hummel T, Bokemeyer C, Stein A, Mann J
CANCER MANAG RES. 2019;11:4493—4504.

Treatment of Metastatic Spindle Epithelial Tumor with Thymus-Like Differentiation (SETTLE) - Long-Term Disease Control by Multimodal Therapy
Quidde J, Alsdorf W, von Amsberg G, Wilczak W, Bokemeyer C
ONCOL RES TREAT. 2018;41(1-2):58-60.

Preventing adverse events of chemotherapy by educating patients about the nocebo effect (RENNO study) - study protocol of a randomized controlled trial with gastrointestinal cancer patients
Quidde J, Pan Y, Salm M, Hendi A, Nilsson S, Oechsle K, Stein A, Nestoriuc Y
BMC CANCER. 2018;18(1):916.

T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker
Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford C, Asemissen A, Thiele B, Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Binder M
INT J CANCER. 2017;140(11):2535-2544.

Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study
Haag G, Stocker G, Quidde J, Jaeger D, Lordick F
BMC CANCER. 2017;17(1):509.

AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer
Kripp M, Prasnikar N, Vehling-Kaiser U, Quidde J, Al-Batran S, Stein A, Neben K, Hannig C, Tessen H, Trarbach T, Hinke A, Hofheinz R
ONCOTARGET. 2017;8(62):105061-105071.

Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer
Quidde J, Denne L, Kutscheidt A, Kindler M, Kirsch A, Kripp M, Petersen V, Schulze M, Seraphin J, Tummes D, Arnold D, Stein A
ONCOL RES TREAT. 2017;40(1-2):21-26.

Das CARE-for-CAYA-Programm. Präventionskonzept für junge Menschen nach Krebserkrankung
Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2017;32(06):479-484.

Versorgung von Patienten nach Krebserkrankung im Kindes-, Jugend- oder jungen Erwachsenenalter
Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A
J Onkol - Z Onkol Fortb. 2017;2017(10):862-866.

Personalizing Maintenance Therapy in Metastatic Colorectal Cancer
Quidde J, Stein A
CURR COLORECT CANC R. 2017;13(3):205-211.

Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study
Creutzfeldt A, Suling A, Oechsle K, Mehnert A, Atanackovic D, Kripp M, Arnold D, Stein A, Quidde J
BMC PALLIAT CARE. 2016;15(1):25.

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®
Gorges T, Stein A, Quidde J, Hauch S, Röck K, Riethdorf S, Joosse S, Pantel K
PLOS ONE. 2016;11(5):e0155126.

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells
Hvichia G, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, Müller V, Loges S, Neves R, Stoecklein N, Wikman H, Riethdorf S, Pantel K, Gorges T
INT J CANCER. 2016;138(12):2894-904.

Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature
Quidde J, Azémar M, Bokemeyer C, Arnold D, Stein A
THER ADV MED ONCOL. 2016;8(3):144-52.

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial
Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller C, Killing B, Depenbusch R, Steffens C, Lange T, Dietrich G, Stoehlmacher J, Reinacher A, Tannapfel A, Trarbach T, Marschner N, Schmoll H, Hinke A, Al-Batran S, Arnold D
ANN ONCOL. 2016;27(12):2203-2210.

Improved nutrition in adolescents and young adults after childhood cancer - INAYA study
Quidde J, von Grundherr J, Koch B, Bokemeyer C, Escherich G, Valentini L, Buchholz D, Schilling G, Stein A
BMC CANCER. 2016;16(1):872.

Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study
Stein A, Quidde J, Schröder J, Göhler T, Tschechne B, Valdix A, Höffkes H, Schirrmacher-Memmel S, Wohlfarth T, Hinke A, Engelen A, Arnold D
BMC CANCER. 2016;16(1):82.

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
Hegewisch-Becker S, Graeven U, Lerchenmüller C, Killing B, Depenbusch R, Steffens C, Al-Batran S, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll H, Arnold D
LANCET ONCOL. 2015;16(13):1355-69.

Survivorship-Programme: Ziele und Inhalte einer strukturierten Betreuung
Schilling G, Stein A, Quidde J, Bokemeyer C
Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2014;3(29):202-205.

Oxaliplatin for colorectal cancer: recent evidence from clinical trials
Stein A, Quidde J, Arnold D
COLORECTAL CANCER. 2013;135-44.

Clinical management of localized colon cancer with capecitabine.
Quidde J, Arnold D, Stein A
CLIN MED INSIGHTS-ON. 2012;6:363-373.

Letzte Aktualisierung aus dem FIS: 24.12.2024 - 23:36 Uhr